Paul R. Sieber, MD, FACS
Sipuleucel-T (Provenge) received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy. We had complete information on 94 patients.
illustrates, most of these men were alive at the time of this review. The median age was 74. Roughly 70% of men with a PSA <22.1 were alive at the time of this review.
Table 1. Survivorship Following Treatment With Sipuleucel-T
... to read the full story